No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 6.0x · 10Y median 6.6x · 46th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 20
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T18:28:36.686Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T18:28:36.686Z. Latest historical point 2022-03-02.
The latest delayed quote for TriSalus Life Sciences, Inc. (TLSI) stock was $4.39 as of Oct 6, 2026, 2:24 PM EDT, up 0.11% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -5.2% · 3-year avg -3.4%/yr · 5-year avg -15.1%/yr
TriSalus Life Sciences, Inc. is an immunotherapy firm dedicated to the research, development, and market introduction of treatments that leverage the body's immune system, primarily targeting liver and pancreatic cancers.
Medical - Devices · Westminster, CO
Next Earnings Date
Nov 12, 2026
37 days away
EPS Estimate
-0.14
Revenue Est.
$14.02M
Last Quarter Results
EPS
$-0.16
vs Estimate
$-0.15
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1TLSI | $270.00M | $4.38 | +0.11% | -5.17% | -15.05% | N/A | N/A |
| 2TMCI | $270.20M | $4.17 | -7.03% | -29.44% | -29.41% | N/A | vs TLSI |
| 3SABS | $270.41M | $2.97 | -4.13% | +50.19% | -50.16% | N/A | vs TLSI |
| 4SCTX | $269.43M | $16.65 | +2.71% | N/A | N/A | N/A | vs TLSI |
| 5VNDA | $270.61M | $4.50 | -1.75% | -15.59% | -23.91% | -11.90% | vs TLSI |
| 6FATE | $271.00M | $2.33 | -4.32% | +100.16% | -46.86% | -2.31% | vs TLSI |
forward FY estimate
N/A
$11.41M
vs Estimate
$10.27M
Consensus Rating
Based on 5 analysts
Average Price Target
$10.40
+137.2% upside
Low
$7.00
Current
$4.38
High
$14.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.14 | $-0.13 | $-0.11 | 3 |
| Quarter ending Dec 2026 | $-0.07 | $-0.06 | $-0.06 | 3 |
| Quarter ending Mar 2027 | $-0.11 | $-0.10 | $-0.09 | 1 |
| Quarter ending Jun 2027 | $-0.10 | $-0.09 | $-0.09 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.36 | $-0.33 | $-0.31 | 3 |
| FY 2027 | $-0.29 | $-0.26 | $-0.25 | 3 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $12.97M | $14.02M | $14.87M | 3 |
| Quarter ending Dec 2026 | $17.39M | $18.80M | $19.94M | 3 |
| Quarter ending Mar 2027 | $15.64M | $16.91M | $17.93M | 1 |
| Quarter ending Jun 2027 | $16.59M | $17.93M | $19.02M | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $50.20M | $53.12M | $56.45M | 3 |
| FY 2027 | $70.42M | $74.51M | $79.18M | 3 |
